LITT and Pembrolizumab in Recurrent Brain Metastasis

Summary

This is an open-label, historically controlled pilot study investigating the immune effect of Laser Interstitial ThermotHerapy (LITT)+ pembrolizumab in adult patients with a primary cancer approved by the FDA for treatment with an immune-checkpoint inhibitor who have recurrent brain metastasis after prior stereotactic radiosurgery (SRS).

Timeline

Start

2020-01-10

Primary completion

2023-12-01

Completion

2023-12-01

Outcome

Outcome not reported

Stopped: “Sponsor terminated”

Drugs

Indications